Over the last 7 days, the United States market has remained flat, yet it has risen by 16% over the past year with expectations of earnings growing annually by a similar rate in the coming years. In this context of steady growth, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and potential to outperform these promising market conditions.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Marker Therapeutics |
61.33% |
65.71% |
★★★★★★ |
|
Palantir Technologies |
27.02% |
31.25% |
★★★★★★ |
|
|
22.20% |
27.96% |
★★★★★★ |
|
Sandisk |
30.23% |
46.19% |
★★★★★★ |
|
Gorilla Technology Group |
54.35% |
95.02% |
★★★★★☆ |
|
Tenaya Therapeutics |
58.52% |
60.10% |
★★★★★☆ |
|
Zscaler |
15.93% |
48.88% |
★★★★★☆ |
|
Duos Technologies Group |
53.76% |
155.11% |
★★★★★☆ |
|
Procore Technologies |
12.08% |
99.98% |
★★★★★☆ |
|
KVH Industries |
25.44% |
135.75% |
★★★★★☆ |
Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: CareDx, Inc. is a company that offers solutions to enhance transplant patient outcomes and organ health globally, with a market cap of approximately $913.70 million.
Operations: The company generates revenue primarily from its biotechnology segment, totaling $379.81 million.
CareDx’s recent launch of VANTx™, an AI-powered platform for transplant data analysis, underscores its innovative approach in the high-tech medical field. This tool enhances clinical research capabilities by providing insights into treatment trends and patient outcomes, reflecting CareDx’s commitment to advancing transplant care through technology. Moreover, with a projected revenue increase to $444 million in 2026 and a notable annual earnings growth rate of 93.6%, CareDx is positioning itself strongly within the tech-driven healthcare sector. The company’s strategic focus on R&D is evident as it continues to invest in groundbreaking technologies like AlloHeme for early cancer relapse detection, further solidifying its role in transforming patient management and outcomes in transplantation medicine.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Daktronics, Inc. specializes in designing, manufacturing, and selling electronic scoreboards and display systems for various applications globally, with a market cap of $1.04 billion.
Operations: The company generates revenue primarily from five segments: Commercial ($181.01 million), Live Events ($295.79 million), International ($76.98 million), Transportation ($71.43 million), and High School Park and Recreation ($177.44 million).
Daktronics has recently showcased its capability to enhance fan experiences through significant digital display installations in major league baseball stadiums, such as the Seattle Mariners and Arizona Diamondbacks. This aligns with a broader trend where venues are increasingly integrating advanced technologies to improve engagement and sponsorship opportunities. Financially, Daktronics reported a robust recovery with third-quarter sales rising to $181.87 million from $149.51 million year-over-year, reflecting strong demand for its innovative solutions. Furthermore, the company’s strategic repurchases of shares underscore confidence in its financial health and future prospects, having reacquired 547,501 shares for $10.56 million recently, signaling positive momentum and operational strength moving forward.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Vishay Precision Group, Inc. operates in the precision measurement and sensing technologies sector across various regions including the United States, Europe, Israel, Asia, and Canada with a market capitalization of $568.73 million.
Operations: Vishay Precision Group generates revenue primarily from three segments: Sensors ($117.17 million), Weighing Solutions ($111.80 million), and Measurement Systems ($80.41 million). The company operates in the precision measurement and sensing technologies sector across multiple regions, contributing to its market presence.
Vishay Precision Group (VPG), despite a challenging year with a net loss in Q4, remains poised for significant earnings growth, projected at 64.8% annually. Recent presentations at high-profile conferences underscore the company’s strategic efforts to communicate its value and future direction effectively. With R&D expenses consistently aligning with industry innovation demands—evidenced by an annual increase to $15 million—VPG is investing in technologies that could drive future revenue streams, currently growing at 6.3% per year. This focus on development and strategic communication highlights VPG’s potential resilience and adaptability within the electronic components sector.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CDNA DAKT and VPG.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com